COMMUNIQUÉS West-GlobeNewswire

-
Cytori Announces Japan Class III Medical Device Approval for Cell Therapy Product
03/12/2018 -
Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia
03/12/2018 -
Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting
03/12/2018 -
OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting
03/12/2018 -
Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting
03/12/2018 -
Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications
03/12/2018 -
Genmab to Hold R&D Update and 2018 ASH Data Review Meeting
03/12/2018 -
GENFIT: Launch of a U.S. Phase 2 investigator-initiated study with nitazoxanide in patients with NASH-induced fibrosis
03/12/2018 -
GENFIT : Lancement aux États-Unis d'une étude de Phase 2 initiée par un investigateur, évaluant nitazoxanide chez des patients avec fibrose NASH
03/12/2018 -
Press release: Terveystalo to become a shareholder in startup company Etsimo Healthcare - harnessing AI to assist the customer and the healthcare professional
03/12/2018 -
Rule 2.9 Announcement
03/12/2018 -
Total voting rights
03/12/2018 -
Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
03/12/2018 -
Helsinn and Mundipharma China Pharmaceutical Announce Approval of ALOXI® IV by the National Medical Products Administration (NMPA)
03/12/2018 -
argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia
03/12/2018 -
argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)
03/12/2018 -
Cellworks AI-Driven Biosimulation Predicted Chemo-resistance in AML and MDS Patients with 90% Accuracy
03/12/2018 -
Cellworks Study Predicted Non-Response to Azacitidine in MDS Patients with 100% Accuracy using AI-Driven Biosimulation
03/12/2018 -
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-20-03 at the 2018 ASH Annual Meeting
03/12/2018
Pages